医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

National Heart Research Institute Singapore and Thermo Fisher Scientific Teams Up to Further Enhance Stem Cell Research Techniques

2014年11月06日 PM01:30
このエントリーをはてなブックマークに追加


 

SINGAPORE

Researchers and medical doctors in Singapore will have a new opportunity to participate in the Pluripotent Stem Cell Training Course, a workshop which showcases the latest pluripotent stem cell technologies, on 10 and 11 November 2014. It is hosted by Thermo Fisher Scientific and the National Heart Research Institute Singapore (NHRIS), the research arm of the National Heart Centre Singapore (NHCS).

The course aligns with Singapore’s government vision to build a vibrant science and technology hub where research and development contributes significantly to a knowledge-intensive, innovative and entrepreneurial economy. Thermo Fisher Scientific is committed to collaborating with the country’s leading institutes to bring cutting-edge technologies to the researchers and labs of Singapore.

Workshop participants from laboratories and institutions across the country will acquire advanced training on culturing and characterizing pluripotent stem cells (iPSCs), as well as reprogramming and derivation techniques. The two-day workshop includes lectures, hands-on lab work, and one-on-one training with expert trainers from Thermo Fisher Scientific.

The workshop will be hosted by Adjunct Assistant Professor Winston Shim, Principal Investigator of Regenerative Medicine, NHRIS, NHCS, a recognized scientist focusing on the functional recovery of the heart utilizing stem cells. While he is known for his research, Dr. Shim is also committed in supporting the country’s medical and applied researchers to promote bringing bench research on stem cells to bedside treatments.

“Technologies that contribute to enhanced speed, efficiency and safety of pluripotent stem cell research have become more and more important as we accelerate our search for discoveries that lead to better healthcare,” said Dr. Shim. “This workshop allows experts to exchange ideas and best practices, and further enhance their knowledge to maximize the ability of our research community.”

“LifeLab Stem Cell Research Centers develop trusted learning programs for the latest techniques in treating human embryonic stem cells (hESCs) and iPSCs,” added Dr. Nirupama Shevde, Senior Stem Cell Scientist and Global Training Manager for Thermo Fisher Scientific, who will lead the workshop. “I’m looking forward to meeting with the stem cell experts of Singapore and to work with Dr. Shim and NHCS scientists to enhance the country’s research abilities.”

“It is an honor to be able to share our standardized and trusted stem cell technologies with one of the most advanced research communities,” said Joydeep Goswami, Asia Pacific and Japan President for the Life Sciences Solutions for Thermo Fisher Scientific. “Thermo Fisher Scientific is expanding our product, service and knowledge offering in Singapore to deliver value and to realize our company mission to enable our customers to make the world healthier, cleaner and safer.”

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our four premier brands – Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

CONTACT

For Thermo Fisher Scientific
Life Sciences Solutions
Atsuko
Igawa, +81-3-6832-9446
Communications
atsuko.igawa@thermofisher.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表